SimBioSys and Ferrum Health Partner on AI-Powered Breast Cancer Surgical Planning

Source: PR Newswire — 2026-07-23

Summary

SimBioSys and Ferrum Health announced a partnership to expand access to SimBioSys's FDA-cleared TumorSight Viz platform through Ferrum's Model Hub, part of Ferrum's AI Governance Suite. TumorSight Viz converts standard breast MRI scans into interactive, patient-specific 3D visualizations, giving surgeons deeper anatomical insight for breast cancer surgical planning. By distributing the tool through Ferrum's enterprise infrastructure, the companies aim to let health systems nationwide deploy, manage, and scale AI-driven surgical planning more easily.

Key Takeaways

• TumorSight Viz is SimBioSys's FDA-cleared AI platform that transforms standard breast MRI into interactive, patient-specific 3D models to support more individualized surgical planning.
• The product will be distributed through Ferrum Health's Model Hub, a component of Ferrum's AI Governance Suite built to help health systems deploy and manage clinical AI tools at scale.
• Stacey Stevens, President and CEO of SimBioSys, said bringing AI into clinical practice "requires more than innovation—it requires practical implementation within health systems."
• Pelu Tran, CEO of Ferrum Health, said TumorSight Viz "brings a new dimension to our platform in breast surgical planning—an area where precision and context are critical."
• The partnership targets enterprise-grade, governed deployment of AI surgical-planning tools rather than point-solution adoption, aiming to make it easier for hospitals to integrate the technology into existing care delivery workflows.
• The deal builds on SimBioSys's prior FDA clearances for TumorSight Viz and its related TumorSight Clinical Decision Support tool for breast cancer surgery.

Discussion

(No questions yet — ask follow-ups via a Claude Code chat session on this repo; answers get appended here.)